Authors : Harmandeep Kaur; Lovepreet Kaur; Dr. Sanjiv Duggal

Volume/Issue : Volume 11 - 2026, Issue 5 - May

Google Scholar : https://tinyurl.com/wuva3c7u

Scribd : https://tinyurl.com/82rd4cvk

DOI : https://doi.org/10.38124/ijisrt/26May1000

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Gastroretentive drug delivery systems (GRDDS) represent an innovative strategy developed to overcome the drawbacks associated with conventional oral dosage forms, such as rapid gastric emptying and poor bioavailability. These systems are specifically designed to increase the residence time of drugs in the stomach, thereby improving drug absorption, particularly for drugs having a narrow absorption window, low solubility at intestinal pH, or those intended for local gastric action, GRDDS employ different mechanisms, including floating, mucoadhesion, swelling, high-density, and raftforming approaches to achieve prolonged gastric retention. Their performance is influenced by various physiological factors, such as gastric pH, motility, and feeding conditions, along with formulation-related factors like size, density, and polymer characteristics. Polymers and excipients play a significant role in controlling drug release and maintaining formulation stability. These systems offer advantages such as enhanced bioavailability, reduced dosing frequency, and improved therapeutic outcomes. However, certain limitations, like variability in gastric retention and formulation complexity, still exist. With continuous advancements in polymer science, nanotechnology, and formulation techniques, GRDDS are expected to play a crucial role in future controlled and targeted drug delivery systems.

Keywords : Gastro-Retentive Drug Delivery System, Gastric Residence Time, Controlled Drug Delivery, Floating Drug Delivery System, Gastrointestinal Physiology.

References :

1. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site specific delivery. Int J Pharmaceutics; 1996. 136:117–139.
2. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery system. Expert Opin Drug Deliv; 2006. 3(2):217–233.
3. Singh BN, Kim KH. Floating drug delivery systems: An approach to controlled drug delivery via gastric retention. J Control Release; 2000. 63:235–239.
4. Dixit N. Floating drug delivery system. J Current Pharmceutical Research; 2011. 7(1):6–20.
5. Robinson J, Lee R. Controlled drug delivery system. 2nd ed. Marcel Dekker; 1987. p. 418.
6. Chawla G, Gupta P, Koradia V, Bansal AK. Gastroretention: A means to address regional variability in intestinal drug absorption. Pharm Technol; 2003. 27(2):50–68.
7. Subrahmanyam CVS, Setty JT. Laboratory manual of physical pharmaceutics. Vallabh Prakashan; 2002. p. 212.
8. Kumar V, Sharma R. Formulation and evaluation of gastroretentive drug delivery systems: Objectives and methodologies. Asian J Pharm; 2022. 16(2):120–128.
9. Sharma D, Sharma A. Gastroretentive drug delivery system: A mini review. Asian Pac J Health Sci; 2014. 1(2):80–89.
10. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms. J Control Release; 2006. 111:1–18.
11. Arora S, Javed A, Ahuja A, Khar RK, Baboota S. Floating drug delivery system: A review. AAPS Pharm SciTech; 2000. 6(3):372–390.
12. Patel GM, Patel HR, Patel M. Floating drug delivery system: An innovative approach to prolong gastric retention. Pharma info; 2007.
13. Seth SD. Textbook of pharmacology. Reed Elsevier; 2005.
14. Sangekar S. Evaluation of effect of food and specific gravity of tablets on gastric retention time. Int J Pharm; 1985. 35:34–53.
15. Whitehead L, Fell JT, Collett JH. Development of a gastroretentive dosage form. Eur J Pharm Sci; 1996. 4:182.
16. Kawashima Y, Niwa T, Takenchi H, Hino T, Ito Y. Hollow microspheres for floating drug delivery system. J Pharm Sci; 1992. 81:135–140.
17. Moes AJ. Gastroretentive dosage forms. Crit.  Rev Ther Drug Carrier Syst; 1993. 10:143–195.
18. Alzeher W, Shaw J, Al-Kassas R. Gastroretentive formulations for improving oral bioavailability of drugs. Current Drug Deliv; 2016. 13(5):646–651.
19. Chein YW. Oral drug delivery system. In: Novel drug delivery system. Marcel Dekker; 1992. p.139.
20. Klusner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release; 2003. 90(2):143–162.
21. Sravya K, Kavitha K, Rupesh Kumar M, Jagdeesh Singh SD. Gastroretentive drug delivery system: A review. Res J Pharm Biol Chem Sci; 2012. 3(3):966–980.
22. Abubakar O, Nur Jun S, Zhang X. Controlled oral delivery of captopril: An overview. Int J Pharm; 2000. p.139–146.
23. Chen J, Blevins WE, Park H, Park K. Gastric retention of super- porous hydrogel composites. J Control Release; 2000. 64:39–51.
24. Nayal AS, Pandey S, Gnanarajan G. Overview on gastroretentive floating tablets. Int J Pharm Chem Sci; 2013. 2(3):1357–1365.
25. Sharma R, Kumar P, Singh V. Role of excipients in GRDDS. J Control Release; 2023. 345:156–165.
26. Verma P, Sharma R. Preparation methods for GRDDS. Asian J Pharm; 2023. 18(2):145–155.
27. Zhang H, Wang Y, Li D. In vivo evaluation of GRDDS. J Control Release; 2020. 320:156–167.
28. Pillay S, Shinde AKJ. Gastroretentive drug delivery system: An overview. 2008. p.543–548.
29. Koner P, Saudagar RB, Daharwal SJ. Gastroretentive drugs: Floating therapy. 2007. 5(1):2211–2215.
30. Khan R. Gastroretentive drug delivery system – A review. Int J Pharm Bio Sci; 2013. 4(2):630–646.
31. Khan M, Sharma P, Gupta S. GRDDS for diabetes management. Diabetes Technol Ther; 2023. 25(4):321–330.
32. Kumar R, Sharma P, Gupta N. GRDDS for hypertension. J Pharm Sci; 2023. 62(4):1050–1062.
33. Sharma A, Gupta S, Patel R. GRDDS in chronic pain management. J Control Release; 2022. 340:251–263.
34. Nayak AK, Maji R, Das B. Gastroretentive drug delivery system: A review. Asian J Pharm Clin Res; 2010. 3(1):2–10.
35. Gupta S, Sharma P, Kumar R. GRDDS in GERD and ulcers. J Pharm Sci; 2023. 58(7):1350–1362.
36. Singh R, Kumar A, Patel S. GRDDS for cardiovascular diseases. J Cardiovasc Pharmacology; 2023. 15(2):123–134.
37. Gray H. Anatomy of the human body.20th ed. Lea and Febiger;1918.
38. Kumar A, Sharma P, Gupta R. AI in GRDDS. J Drug Deliv Sci Technol; 2023. 76:102–110.
39. Johnson L, Smith R, Patel A. Monitoring in GRDDS. J Control Release; 2023. 350:55–65.
40. Sharma R, Gupta P, Singh A. Spatial analysis in GRDDS. Int J Geospatial Health; 2023. 15(4):235–246.
41. Thompson H, Lee C, Kumar V. Sustainability in GRDDS. Adv Drug Deliv Rev; 2023. 178:123–135.
42. Singh R, Sharma P, Gupta A. User-centric design in GRDDS. J Drug Deliv Sci Technol; 2023. 68:140–150.
43. Garcia M, Chen Y, Patel R. Interdisciplinary collaboration in GRDDS. Int J Pharm; 2023. 593:120–130.
44. Patel R, Gupta S, Kumar R. Policy integration in GRDDS. J Pharm Policy Pract; 2023. 15(2):102–112.
45. Sharma R, Gupta S, Patel A. Global applications of GRDDS. J Control Release; 2023. 340:112–124.
46. Anderson T, Smith J, Lee K. Ethical considerations in GRDDS. J Med Ethics; 2023. 49(2):95–105.
47. Wu W, Zhou Q, Zhang HB, Ma GD, Fu CD. Nimodipine floating tablets study. Yao Xue Bao; 1997. 32:786–790.
48. Shashi KM. Nanoparticles in modern medicine: State of the art and future challenges. International Journal of Nanomedicine. 2007; 2:129–141.
49. Chaves de Souza MP, Sabio RM, Ribeiro TC, Santos AM, Meneguin AB, Chorili M. Highlighting the impact of chitosan on the development of gastroretentive drug delivery systems. International Journal of Biological Macromolecules. 2020; 159:804–822.
50. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacological Reports. 2012; 64:1020–1037.
51. Patil J, Sayyed H, Suryawanshi H, Patil B. Formulation and evaluation of verdant tablets containing saponin-coalesced silver nanoparticles from fenugreek seed extract. Chemical Proceedings. 2022; 8:56.
52. Sharma A, Goyal AK, Rathi G. Development and characterization of gastroretentive high-density pellets loaded with zero valent iron nanoparticles. Journal of Pharmaceutical Sciences. 2018; 107:2663–2673.
53. Umamaheshwari RB, Ramteke S, Jain NK. Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbil model. AAPS Pharm SciTech. 2004; 5:32.
54. Dave BS, Amin AF, Patel MM. Gastroretentive drug delivery system of ranitidine hydrochloride: Formulation and in vitro evaluation. AAPS Pharm SciTech. 2004; 5:34.
55. Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive drug delivery systems for improving drug bioavailability. International Journal of Pharmaceutics. 2016; 510:144–158.
56. Prajapati, V.D.; Jani, G.K.; Khutliwala, T.A.; Zala, B.S. Raft forming system—An upcoming approach of gastroretentive drug delivery system. J. Control. Release 2013, 168, 151–165.
57. Hwang, S.-J.; Park, H.; Park, K. Gastric retentive drug-delivery systems. Crit. Rev. Ther. Drug 1998, 15.
58. Shaha, S.; Patel, J.; Pundarikakshudu, K.; Patel, N. An overview of a gastro-retentive floating drug delivery system. Asian J. Pharm. Sci. 2009, 4, 65–80
59. Klausner, E.A.; Lavy, E.; Friedman, M.; Hoffman, A. Expandable gastroretentive dosage forms. J. Control. Release 2003, 90, 143–162.
60. Bardonnet, P.; Faivre, V.; Pugh, W.; Piffaretti, J.; Falson, F. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. J. Control. Release 2006, 111, 1–18.
61. Chen, Y.-C.; Ho, H.-O.; Lee, T.-Y.; Sheu, M.-T. Physical characterizations and sustained release profiling of gastroretentive drug delivery systems with improved floating and swelling capabilities. Int. J. Pharm. 2013, 441, 162–169.
62. Streubel, A.; Siepmann, J.; Bodmeier, R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr. Opin. Pharmacol. 2006, 6, 501–508.
63. Abouelatta, S.M.; Aboelwafa, A.A.; El-Gazayerly, O.N. Gastroretentive raft liquid delivery system as a new approach to release extension for carrier-mediated drug. Drug Deliv. 2018, 25, 1161–1174.
64. Youssef, N.A.H.A.; Kassem, A.A.; El-Massik, M.A.E.; Boraie, N.A. Development of gastroretentive metronidazole floating raft system for targeting Helicobacter pylori. Int. J. Pharm. 2015, 486, 297–305.
65. Bhalla, S.; Nagpal, M. Comparison of various generations of super porous hydrogels based on chitosan-acrylamide and in vitro drug release. ISRN Pharm. 2013, 2013, 624841.
66. Awasthi, R.; Kulkarni, G.T. Decades of research in drug targeting to the upper gastrointestinal tract using gastroretention technologies: Where do we stand? Drug Deliv. 2016, 23, 378–394.
67. Noyes, A. A., & Whitney, W. R. The rate of solution of solid substances in their own solutions. Journal of the American Chemical Society; 1897; 19: 930.
68. Nernst, W. Theory of the dissolution rate. Zeitschrift für Physikalische Chemie; 1904; 47: 52.
69. Brunner, E. Diffusion and dissolution studies. Zeitschrift für Physikalische Chemie; 1904; 47: 56.
70. Varma MV, Kaushal AM, Garg A, Garg S. Factors affecting mechanism and kinetics of drug release from matrix-based oral controlled drug delivery systems. Int J Pharm. 2004.
71. Meola T, Russo F, Montone E, et al. RESTORE: regulatory aspects for gastroretentive systems—challenges and pathways. Regul Aff J. 2021; 32(1): 1–12
72. Patel M, Sharma V, Shah S, Joshi J. In vitro–in vivo correlation strategies for GRDDS. Eur J Pharm Sci. 2019; 127: 322–31.
73. Jain A, Gupta Y, Sharma R. In vitro models and IVIVC for floating tablets. J Pharm Biomed Anal. 2016; 125: 40–7.
74. Bolla PK, Narala A, Bandi H, et al. Recent patents on mucoadhesive and floating GRDDS. Expert Opin Ther Pat. 2019; 29(8): 613–25
75. Chaturvedi K. Recent patented gastroretentive technologies. Recent Pat Drug Deliv Formul. 2011; 5(1): 14–25
76. Garg A, Gupta G, Garg B. GRDDS patents: trends and patent landscape. World Patent Inf. 2018; 55: 30–41.
77. Saxena R, Dwivedi R, Saxena A. GRDDS for pediatric and geriatric populations: design adjustments. Int J Pharm. 2015; 482(1–2): 50–9.
78. Alqahtani, A. A., Mohammed, A. A., Fatima, F., & Ahmed, M. M. (2023). Fused deposition modelling 3D-printed gastro-retentive floating device for propranolol HCl tablets. Polymers, 15(17), 3554 https://doi.org/10.3390/polym15173554.
79. Rahamathulla, M., Saisivam, S., Alshetaili, A., Hani, U., Gangadharappa, H. V., Alshehri, S., Ghoneim, M. M., & Shakeel, F. (2021). Design and evaluation of losartan potassium effervescent floating matrix tablets: In vivo X-ray imaging and pharmacokinetic studies in albino rabbits. Polymers, 13(20), 3410.3390/polym13203476. PMID: 34685235; PMCID: PMC8538939.
80. Acharya, S., Pandey, J., Joshi, H. P., Parajuli, G., Poudel, N., Poudel, S., & Gurung, S. (2022). Formulation and evaluation of gastro retentive floating tablet of amlodipine besylate using natural organic polymers. International Journal of Applied Pharmaceutics, 227–234.
81. Mora-Castaño G, Millán-Jiménez M, Caraballo I. Hydrophilic High Drug-Loaded 3D Printed Gastroretentive System with Robust Release Kinetics. Pharmaceutics. 2023; 15(3):842. https://doi.org/10.3390/pharmaceutics15030842.
82. Huh, H. W., Na, Y. G., Kang, H., Kim, M., Han, M. G., Pham, T. M. A., Lee, H., Baek, J. S., Lee, H. K., & Cho, C. W. (2021). Novel self-floating tablet for enhanced oral bioavailability of metformin based on cellulose. International Journal of Pharmaceutics, 592, 120113. https://doi.org/10.1016/j.ijpharm.2020.120113⁠.
83. Yang, H. S., & Kim, D. W. (2023). Fabrication of gastro-floating famotidine tablets: Hydroxypropyl methylcellulose-based semisolid extrusion 3D printing. Pharmaceutics, 15(2), 316. https://doi.org/10.3390/pharmaceutics15020316⁠.
84. Israr, M., Pugliese, N., Farid, A., Ghazanfar, S., Di Cerbo, A., Muzammal, M., Alamri, A. S., Basheeruddin Asdaq, S. M., Ahmad, A., & Khan, K. A. (2022). Preparation and characterization of controlled-release floating bilayer tablets of esomeprazole and clarithromycin. Molecules, 27(10), 3242. https://doi.org/10.3390/molecules27103242⁠.
85. Raafat, A. I., Kamal, H., Sharada, H. M., Elhalim, S. A. A., & Mohamed, R. D. (2021). Radiation development of gastroretentive amoxicillin trihydrate floating-alginate based beads for the treatment of Helicobacter pylori. Radiation Physics and Chemistry, 179, 109268. https://doi.org/10.1016/j.radphyschem.2020.109268⁠.
86. Jiang, Y. K., Cheng, W. T., Chen, L. C., Sheu, M. T., & Lin, H. L. (2023). Development of a swellable and floating gastroretentive drug delivery system (sfGRDDS) of ciprofloxacin hydrochloride. Pharmaceutics, 15(5), 1428. https://doi.org/10.3390/pharmaceutics15051428⁠
87. Samanta, R., Nayak, S. K., Das, B. K., & Nayak, A. K. (2023). Chitosan–carboxymethyl tamarind gum in situ polyelectrolyte complex-based floating capsules of ofloxacin: In vitro–in vivo studies. International Journal of Biological Macromolecules, 253, 127507. https://doi.org/10.1016/j.ijbiomac.2023.127507⁠.
88. Lalge, R., Thipsay, P., Shankar, V. K., Maurya, A., Pimparade, M. B., Bandari, S., Zhang, F., Murthy, S. N., & Repka, M. A. (2019). Preparation and evaluation of cefuroxime axetil gastro-retentive floating drug delivery system via hot melt extrusion technology. International Journal of Pharmaceutics, 566, 520–531. https://doi.org/10.1016/j.ijpharm.2019.06.021⁠.
89. Hou, Z., Cheng, X., Zhao, X., Lin, J., Zhang, H., Li, Y., & Ding, J. (2023). Design and evaluation of gastro-swelling/gastro-floating sustained-release tablets of brivaracetam for epilepsy therapy. International Journal of Pharmaceutics, 644, 123301. https://doi.org/10.1016/j.ijpharm.2023.123301⁠.
90. Khizer, Z., Akram, M. R., Tahir, M. A., Liu, W., Lou, S., Conway, B. R., & Ghori, M. U. (2023). Personalised 3D-printed mucoadhesive gastroretentive hydrophilic matrices for managing overactive bladder (OAB). Pharmaceuticals, 16(3), 372. https://doi.org/10.3390/ph16030372⁠.
91. Kim, S., Hwang, K. M., Park, Y. S., Nguyen, T. T., & Park, E. S. (2018). Preparation and evaluation of non-effervescent gastroretentive tablets containing pregabalin for once-daily administration and dose proportional pharmacokinetics. International Journal of Pharmaceutics, 550(1–2), 160–169. https://doi.org/10.1016/j.ijpharm.2018.08.038⁠
92. Ahmad, S., Khan, J. A., Kausar, T. N., Mahnashi, M. H., Alasiri, A., Alqahtani, A. A., Alqahtani, T. S., Walbi, I. A., Alshehri, O. M., & Elnoubi, O. A. (2023). Preparation, characterization and evaluation of flavonolignan silymarin effervescent floating matrix tablets for enhanced oral bioavailability. Molecules, 28(6), 2606. https://doi.org/10.3390/molecules28062606⁠.
93. Zhang, R., Shi, H., Li, S., Zhang, H., Zhang, D., Wu, A., Zhang, C., Li, C., Fu, X., Chen, S., Shi, J., Tian, Y., Wang, S., Wang, Y., & Liu, H. (2023). A double-layered gastric floating tablet for zero-order controlled release of dihydromyricetin: Design, development, and in vitro/in vivo evaluation. International Journal of Pharmaceutics, 638, 122929. https://doi.org/10.1016/j.ijpharm.2023.122929⁠.
94. Mathew, G., Joseph, L., & Kanaka, V. S. (2017). Formulation and evaluation of floating oral in-situ gel of microwave induced piroxicam-cyclodextrin solid dispersion. International Journal of Institutional Pharmacy and Life Science, 7(6), 2249–2257.
95. Dey, S. K., De, P. K., De, A., Ojha, S., De, R., Mukhopadhyay, A. K., & Samanta, A. (2016). Floating mucoadhesive alginate beads of amoxicillin trihydrate: A facile approach for Helicobacter pylori eradication. International Journal of Biological Macromolecules, 89, 622–631.
96. Agarwal, V., & Mishra, B. (1999). Design, development and biopharmaceutical properties of buccoadhesive compacts of pentazocine. Drug Development and Industrial Pharmacy, 25(6), 701–709.
97. Mohammed, F. A., & Khedr, H. (2003). Preparation and in vitro/in vivo evaluation of the buccal bioadhesive properties of slow-release tablets containing miconazole nitrate. Drug Development and Industrial Pharmacy, 29(3), 321–337.
98. Chowdary, K., Hussainy, S. A., & others. (2012). Formulation and evaluation of floating tablets of gliclazide employing HPMC K100M, starch acetate and Carbopol 934P. Asian Journal of Pharmaceutical and Health Sciences, 2(2), 301–319.
99. Abdelwahd, A., & Abdul Rasool, B. K. (2022). Optimizing and evaluating the transdermal permeation of hydrocortisone transfersomes formulation based on digital analysis of the in vitro drug release and ex vivo studies. Recent Advances in Drug Delivery and Formulation, 16(2), 122–144.
100. Teaima, M. H., Abdel Hamid, M. M., Shoman, N. A., Jasti, B. R., El-Nabarawi, M. A., & Yasser, M. (2020). Formulation, characterization and comparative pharmacokinetic study of bupropion floating raft system as a promising approach for treating depression. Journal of Pharmaceutical Sciences, 109(11), 3451–3461.
101. Abou Youssef, N. A. H., Kassem, A. A., El-Massik, M. A. E., & Boraie, N. A. (2015). Development of gastroretentive metronidazole floating raft system for targeting Helicobacter pylori. International Journal of Pharmaceutics, 486(1–2), 297–305.
102. Kerdsakundee, N., Mahattanadul, S., & Wiwattanapatapee, R. (2015). Development and evaluation of gastroretentive raft forming systems incorporating curcumin-Eudragit® EPO solid dispersions for gastric ulcer treatment. European Journal of Pharmaceutics and Biopharmaceutics, 94, 513–520.
103. Mandel, K. G., Daggy, B. P., Brodie, D. A., & Jacoby, H. I. (2000). Alginate-raft formulations in the treatment of heartburn and acid reflux. Alimentary Pharmacology & Therapeutics, 14(6), 669–690.